<p>TGA 批准使 Owlet 的临床验证、获奖的婴儿健康监测器能够在区域内推出；Owlet360™订阅标志着公司经常性收入平台的首次国际扩展。</p>
<p>悉尼 --（商业资讯）--Owlet, Inc.（“Owlet” 或 “公司”）（纽约证券交易所代码：OWLT），智能婴儿监测的先驱，今天宣布 Dream Sock™现已在澳大利亚和新西兰的家庭中推出。Dream Sock 最近获得了澳大利亚治疗用品管理局（TGA）的批准，符合该地区严格的医疗器械标准。随着这一里程碑的达成，家庭现在可以通过 Owlet 的本地网站和精选零售合作伙伴购买 Dream Sock。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg"/></p>
<p>Owlet 在澳大利亚和新西兰推出 TGA 批准的 Dream Sock。</p>
<p>“将 Owlet 的 TGA 批准的儿科健康监测器带到澳大利亚和新西兰是我们国际增长战略中的重要一步，因为父母们正在积极寻找可信赖的、经过医学验证的解决方案，” Owlet 的总裁兼首席执行官 Jonathan Harris 表示。“我们通过直接面向消费者和领先的专业零售渠道，将 Dream Sock 的临床级监测带给 ANZ 家庭，同时进一步扩展 Owlet360 订阅服务，以支持我们在该地区不断增长的客户基础。”</p>
<p>Dream Sock 是一款为 0-18 个月（2.5–13.6 公斤）婴儿设计的可穿戴智能婴儿监测器。使用先进的、经过临床验证的技术，Dream Sock 跟踪关键生命体征，包括脉搏率、氧气水平和睡眠趋势。通过 Owlet Dream App（可在 iOS 和 Android 上使用），实时查看洞察，同时 App 和包含的基站在读数超出预设范围时提供通知。Dream Sock 结合了父母所需的安心与他们所期望的医疗级准确性，使家庭能够获得更多信息，以做出更明智的护理决策。</p>
<p>与 Dream Sock 的推出相结合，Owlet 在澳大利亚和新西兰推出 Owlet360，标志着公司订阅服务的首次国际推广。Owlet Dream App 将继续提供核心的脉搏率和氧气监测以及关键通知，且无需费用。Owlet360 通过个性化指导、专家支持的资源和更深入的分析，提供更高价值的体验，旨在补充 Dream Sock 的实时生命体征监测。订阅功能包括每日睡眠报告和脉搏率、氧气、运动、舒适温度和房间环境指标的扩展趋势洞察。Owlet360 的扩展支持 Owlet 多元化收入的战略，并随着时间的推移增加经常性、高利润的订阅贡献。</p>
<p>Dream Sock 和 Owlet360 现在可以通过 Owlet 的电子商务网站和精选零售合作伙伴在澳大利亚和新西兰购买。Dream Sock 还可以与公司的 Cam® 2 配对，并作为 Dream Duo™购买。家庭可以访问 www.owletcare.com 或 www.owletcare.com.au 进行购买、探索功能或了解 Dream Sock 和 Owlet360 如何协同工作以支持婴儿健康。</p>
<p><strong>关于 Owlet, Inc.</strong></p>
<p>Owlet, Inc.（纽约证券交易所代码：OWLT）是一家领先的儿科健康平台，是全球唯一提供美国 FDA 批准和国际医学认证的可穿戴儿科监测器的公司，直接在家中提供医院级技术。我们的获奖儿科产品和创新软件结合了经过临床测试的监测系统、集成的视频平台和简单易用的应用程序，为父母提供实时健康洞察，以便随时了解孩子的健康状况，支持安稳的睡眠，并提供安心。自 2012 年以来，超过 250 万父母信任 Owlet 监测他们孩子的健康和睡眠。这一采用推动了全球最大的儿科健康和睡眠数据集合之一，推动了弥合医院与家庭之间关键差距的创新。Owlet 通过将先进的医疗技术与消费者友好的设计相结合，推动儿科健康的新标准。我们的使命简单而雄心勃勃：为每个婴儿和每个家庭提供最佳的生活起点。了解更多信息，请访问 www.owletcare.com，并在 LinkedIn 和 Instagram 上关注我们以获取公司新闻和更新。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》（“改革法”）意义上的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明，包括但不限于关于公司对 Dream Sock™的认证和推出以及在澳大利亚、新西兰及其他国际市场推出 Owlet360™的预期；Dream Sock 和 Owlet360 的可用性、采用情况和商业成功；公司扩大国际市场、丰富产品和订阅服务、实现收入多样化以及随着时间推移增加经常性高利润订阅贡献的能力；公司的增长前景；以及潜在市场反应和竞争定位。在某些情况下，您可以通过 “估计”、“可能”、“相信”、“计划”、“预期”、“预料”、“打算”、“目标”、“潜在”、“即将”、“展望”、“指引” 等术语识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明基于公司在作出该声明时的预期，仅在作出声明的日期有效，并且受到多种风险、不确定性和其他因素的影响。对于所有这些前瞻性声明，公司主张根据改革法享有前瞻性声明的安全港保护。公司的实际结果、表现或成就可能与其前瞻性声明中表达或暗示的未来结果、表现或成就有重大差异。许多重要因素可能影响公司的未来结果，并导致这些结果与公司前瞻性声明中表达或暗示的结果有重大差异。这些因素包括但不限于：(i) Dream Sock 和 Owlet360 在澳大利亚、新西兰及其他国际市场的可用性、采用情况和商业成功，以及 Owlet 其他产品、平台和相关软件服务的商业成功；(ii) Owlet 产品的监管路径，包括向 FDA 及美国以外的类似监管机构提交的申请、采取的行动以及监管机构的决定和回应，以及 Owlet 获得和维持其产品的监管批准或认证及其他监管要求和法律程序的能力；(iii) 公司及其合作伙伴在数据隐私、安全以及健康信息的交换和使用方面的义务（包括 HIPAA、HITECH 及类似法律，以及对这些活动的不断变化的要求），以及网络安全事件的风险或适用标准或解释的变化；(iv) Owlet 与第三方技术、云、制造和分销合作伙伴的关系的表现，以及 Owlet 维持和扩大这些关系的能力；(v) Owlet 的竞争以及公司盈利性增长和管理增长的能力；(vi) Owlet 实施战略举措、降低成本、增加收入、开发和推出新产品、创新和提升现有产品、满足客户需求以及适应消费者偏好和零售趋势变化的能力；(vii) Owlet 获取、维护和保护其知识产权以及满足有关隐私和数据保护的监管要求的能力；(viii) Owlet 维持与渠道合作伙伴、客户、制造商和供应商关系的能力；(ix) 遵守适用法律或法规的影响；(x) 由于超出公司控制的经济和其他条件对 Owlet 的业务、财务状况、运营、供应链和物流的影响和干扰；(xi) 其他经济、商业、监管、竞争或其他因素的负面影响，例如可自由支配的消费者支出和消费者偏好的变化；以及 (xii) 公司其他发布、公开声明和向美国证券交易委员会（“SEC”）提交的文件中列出的其他风险和不确定性，包括在公司截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分中识别的因素，以及这些因素可能会不时在公司向 SEC 提交的其他文件中更新。所有归因于公司或代表公司行事的任何人的前瞻性声明均完全受到上述警示声明的限制。此外，公司在一个不断发展的环境中运营。新的风险因素和不确定性可能会不时出现，而公司目前认为不重要的因素可能会变得重要，公司无法预测这些事件或它们可能如何影响 Owlet。除法律要求外，公司不承担在本新闻稿日期之后更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，尽管 Owlet 可能会不时这样做。公司不支持任何第三方可能做出的关于未来表现的预测。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDQxOTA2NDVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDQxOTA2NDVyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251204190645/en/</p>
<p><strong>媒体联系：</strong></p>
<p>pr@owletcare.com</p>
<p><strong>投资者联系：</strong></p>
<p>ir@owletcare.com</p>
<p>来源：Owlet, Inc.</p>

OWLT

<p>Owlet, Inc. 在澳大利亚和新西兰推出了其获得 TGA 批准的 Dream Sock™，标志着其国际扩张的重要一步。Dream Sock 是一款智能婴儿健康监测器，现在可以通过 Owlet 的本地网站和部分零售合作伙伴购买。此次发布还在该地区推出了 Owlet360 订阅服务，增强了公司的经常性收入平台。Dream Sock 提供婴儿的实时健康洞察，而 Owlet360 则提供个性化指导和分析，支持 Owlet 多元化收入和增加订阅贡献的战略</p>

<p><em>TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription marks first international expansion of the Company’s recurring-revenue platform.</em></p>
<div class="lb-trans"><p>TGA 批准使 Owlet 的临床验证、获奖的婴儿健康监测器能够在区域内推出；Owlet360™订阅标志着公司经常性收入平台的首次国际扩展。</p>
</div><p>SYDNEY--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ is now available for families across Australia and New Zealand. Dream Sock recently received approval from Australia’s Therapeutic Goods Administration (TGA), meeting rigorous medical device standards in the region. With this milestone achieved, families can now purchase Dream Sock through Owlet’s local website and select retail partners.</p>
<div class="lb-trans"><p>悉尼 --（商业资讯）--Owlet, Inc.（“Owlet” 或 “公司”）（纽约证券交易所代码：OWLT），智能婴儿监测的先驱，今天宣布 Dream Sock™现已在澳大利亚和新西兰的家庭中推出。Dream Sock 最近获得了澳大利亚治疗用品管理局（TGA）的批准，符合该地区严格的医疗器械标准。随着这一里程碑的达成，家庭现在可以通过 Owlet 的本地网站和精选零售合作伙伴购买 Dream Sock。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg" alt="" original-src="https://mms.businesswire.com/media/20251204190645/en/2661261/4/Owlet_Dream_Sock.jpg"/></p>
<p>Owlet launches TGA-Approved Dream Sock in ANZ.</p>
<div class="lb-trans"><p>Owlet 在澳大利亚和新西兰推出 TGA 批准的 Dream Sock。</p>
</div><p>“Bringing Owlet’s TGA-approved pediatric health monitor to Australia and New Zealand represents a meaningful step in our international growth strategy, as parents are actively seeking trusted, medically-validated solutions,” said Jonathan Harris, Owlet’s President and CEO. “We are bringing the clinical-grade monitoring of Dream Sock to ANZ families through both direct-to-consumer and leading specialty retail channels, while also extending Owlet360 subscription services further to support our growing base of customers in the region.”</p>
<div class="lb-trans"><p>“将 Owlet 的 TGA 批准的儿科健康监测器带到澳大利亚和新西兰是我们国际增长战略中的重要一步，因为父母们正在积极寻找可信赖的、经过医学验证的解决方案，” Owlet 的总裁兼首席执行官 Jonathan Harris 表示。“我们通过直接面向消费者和领先的专业零售渠道，将 Dream Sock 的临床级监测带给 ANZ 家庭，同时进一步扩展 Owlet360 订阅服务，以支持我们在该地区不断增长的客户基础。”</p>
</div><p>Dream Sock is a wearable smart baby monitor designed for infants ages 0-18 months (2.5–13.6 kg). Using advanced, clinically validated technology, Dream Sock tracks key vitals, including pulse rate, oxygen level, and sleep trends. Insights are viewable in real-time through the Owlet Dream App (available via iOS and Android), while both the App and the included Base Station provide notifications if readings fall outside preset ranges. Dream Sock combines the reassurance parents want with the medical-grade accuracy they expect, empowering families with the information to make more informed care decisions.</p>
<div class="lb-trans"><p>Dream Sock 是一款为 0-18 个月（2.5–13.6 公斤）婴儿设计的可穿戴智能婴儿监测器。使用先进的、经过临床验证的技术，Dream Sock 跟踪关键生命体征，包括脉搏率、氧气水平和睡眠趋势。通过 Owlet Dream App（可在 iOS 和 Android 上使用），实时查看洞察，同时 App 和包含的基站在读数超出预设范围时提供通知。Dream Sock 结合了父母所需的安心与他们所期望的医疗级准确性，使家庭能够获得更多信息，以做出更明智的护理决策。</p>
</div><p>In conjunction with the Dream Sock launch, Owlet is introducing Owlet360 in Australia and New Zealand, marking the first international rollout of the Company’s subscription service. The Owlet Dream App will continue to provide core pulse rate and oxygen tracking and critical notifications at no cost. Owlet360 adds a higher-value experience through personalized guidance, expert-backed resources, and deeper analytics designed to complement Dream Sock’s real-time vitals monitoring. Subscription features include daily sleep reports and expanded trend insights across pulse rate, oxygen, movement, comfort temperature, and room environment metrics. The Owlet360 expansion supports Owlet’s strategy to diversify revenue and increase recurring, higher-margin subscription contribution over time.</p>
<div class="lb-trans"><p>与 Dream Sock 的推出相结合，Owlet 在澳大利亚和新西兰推出 Owlet360，标志着公司订阅服务的首次国际推广。Owlet Dream App 将继续提供核心的脉搏率和氧气监测以及关键通知，且无需费用。Owlet360 通过个性化指导、专家支持的资源和更深入的分析，提供更高价值的体验，旨在补充 Dream Sock 的实时生命体征监测。订阅功能包括每日睡眠报告和脉搏率、氧气、运动、舒适温度和房间环境指标的扩展趋势洞察。Owlet360 的扩展支持 Owlet 多元化收入的战略，并随着时间的推移增加经常性、高利润的订阅贡献。</p>
</div><p>Dream Sock and Owlet360 are now available in Australia and New Zealand via Owlet’s ecommerce websites and through select retail partners. Dream Sock can also be paired with the Company’s Cam® 2 and purchased as the Dream Duo™. Families can visit www.owletcare.com or www.owletcare.com.au to purchase, explore features, or learn more about how Dream Sock and Owlet360 work together to support infant well-being.</p>
<div class="lb-trans"><p>Dream Sock 和 Owlet360 现在可以通过 Owlet 的电子商务网站和精选零售合作伙伴在澳大利亚和新西兰购买。Dream Sock 还可以与公司的 Cam® 2 配对，并作为 Dream Duo™购买。家庭可以访问 www.owletcare.com 或 www.owletcare.com.au 进行购买、探索功能或了解 Dream Sock 和 Owlet360 如何协同工作以支持婴儿健康。</p>
</div><p><strong>About Owlet, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Owlet, Inc.</strong></p>
</div><p>Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.</p>
<div class="lb-trans"><p>Owlet, Inc.（纽约证券交易所代码：OWLT）是一家领先的儿科健康平台，是全球唯一提供美国 FDA 批准和国际医学认证的可穿戴儿科监测器的公司，直接在家中提供医院级技术。我们的获奖儿科产品和创新软件结合了经过临床测试的监测系统、集成的视频平台和简单易用的应用程序，为父母提供实时健康洞察，以便随时了解孩子的健康状况，支持安稳的睡眠，并提供安心。自 2012 年以来，超过 250 万父母信任 Owlet 监测他们孩子的健康和睡眠。这一采用推动了全球最大的儿科健康和睡眠数据集合之一，推动了弥合医院与家庭之间关键差距的创新。Owlet 通过将先进的医疗技术与消费者友好的设计相结合，推动儿科健康的新标准。我们的使命简单而雄心勃勃：为每个婴儿和每个家庭提供最佳的生活起点。了解更多信息，请访问 www.owletcare.com，并在 LinkedIn 和 Instagram 上关注我们以获取公司新闻和更新。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the certification and launch of Dream Sock™ and the introduction of Owlet360™in Australia, New Zealand and other international markets; the availability, adoption and commercial success of Dream Sock and Owlet360; the Company’s ability to expand its international footprint, broaden its product and subscription offerings, diversity revenue streams and increase recurring, higher-margin subscription contribution over time; and the Company’s growth prospects; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability, adoption, and commercial success of Dream Sock and Owlet360 in Australia, New Zealand, and other international markets, and the commercial success of Owlet’s other products, platform and related software services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》（“改革法”）意义上的前瞻性声明。本新闻稿中所有与历史事实无关的声明应视为前瞻性声明，包括但不限于关于公司对 Dream Sock™的认证和推出以及在澳大利亚、新西兰及其他国际市场推出 Owlet360™的预期；Dream Sock 和 Owlet360 的可用性、采用情况和商业成功；公司扩大国际市场、丰富产品和订阅服务、实现收入多样化以及随着时间推移增加经常性高利润订阅贡献的能力；公司的增长前景；以及潜在市场反应和竞争定位。在某些情况下，您可以通过 “估计”、“可能”、“相信”、“计划”、“预期”、“预料”、“打算”、“目标”、“潜在”、“即将”、“展望”、“指引” 等术语识别前瞻性声明，尽管并非所有前瞻性声明都包含这些识别词。前瞻性声明基于公司在作出该声明时的预期，仅在作出声明的日期有效，并且受到多种风险、不确定性和其他因素的影响。对于所有这些前瞻性声明，公司主张根据改革法享有前瞻性声明的安全港保护。公司的实际结果、表现或成就可能与其前瞻性声明中表达或暗示的未来结果、表现或成就有重大差异。许多重要因素可能影响公司的未来结果，并导致这些结果与公司前瞻性声明中表达或暗示的结果有重大差异。这些因素包括但不限于：(i) Dream Sock 和 Owlet360 在澳大利亚、新西兰及其他国际市场的可用性、采用情况和商业成功，以及 Owlet 其他产品、平台和相关软件服务的商业成功；(ii) Owlet 产品的监管路径，包括向 FDA 及美国以外的类似监管机构提交的申请、采取的行动以及监管机构的决定和回应，以及 Owlet 获得和维持其产品的监管批准或认证及其他监管要求和法律程序的能力；(iii) 公司及其合作伙伴在数据隐私、安全以及健康信息的交换和使用方面的义务（包括 HIPAA、HITECH 及类似法律，以及对这些活动的不断变化的要求），以及网络安全事件的风险或适用标准或解释的变化；(iv) Owlet 与第三方技术、云、制造和分销合作伙伴的关系的表现，以及 Owlet 维持和扩大这些关系的能力；(v) Owlet 的竞争以及公司盈利性增长和管理增长的能力；(vi) Owlet 实施战略举措、降低成本、增加收入、开发和推出新产品、创新和提升现有产品、满足客户需求以及适应消费者偏好和零售趋势变化的能力；(vii) Owlet 获取、维护和保护其知识产权以及满足有关隐私和数据保护的监管要求的能力；(viii) Owlet 维持与渠道合作伙伴、客户、制造商和供应商关系的能力；(ix) 遵守适用法律或法规的影响；(x) 由于超出公司控制的经济和其他条件对 Owlet 的业务、财务状况、运营、供应链和物流的影响和干扰；(xi) 其他经济、商业、监管、竞争或其他因素的负面影响，例如可自由支配的消费者支出和消费者偏好的变化；以及 (xii) 公司其他发布、公开声明和向美国证券交易委员会（“SEC”）提交的文件中列出的其他风险和不确定性，包括在公司截至 2024 年 12 月 31 日的年度报告的 “风险因素” 部分中识别的因素，以及这些因素可能会不时在公司向 SEC 提交的其他文件中更新。所有归因于公司或代表公司行事的任何人的前瞻性声明均完全受到上述警示声明的限制。此外，公司在一个不断发展的环境中运营。新的风险因素和不确定性可能会不时出现，而公司目前认为不重要的因素可能会变得重要，公司无法预测这些事件或它们可能如何影响 Owlet。除法律要求外，公司不承担在本新闻稿日期之后更新任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因，尽管 Owlet 可能会不时这样做。公司不支持任何第三方可能做出的关于未来表现的预测。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMDQxOTA2NDVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251204190645r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251204190645/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251204190645/en/</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>pr@owletcare.com</p>
<div class="lb-trans"><p>pr@owletcare.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>ir@owletcare.com</p>
<div class="lb-trans"><p>ir@owletcare.com</p>
</div><p>Source: Owlet, Inc.</p>
<div class="lb-trans"><p>来源：Owlet, Inc.</p>
</div>

Owlet Launches TGA-Approved Dream Sock™ in Australia & New Zealand, Expanding International Footprint and Bringing Trusted Pediatric Health Monitoring to More Families Worldwide | OWLT Stock News

Owlet 在澳大利亚和新西兰推出获得 TGA 批准的 Dream Sock™，扩大其国际影响力，将值得信赖的儿科健康监测服务带给全球更多家庭 | OWLT 股票新闻